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Abstract
Purpose Reports on cardiac problems with oral proton
pump inhibitors have caused extensive safety reviews by
the US Food and Drug Administration. We provide addi-
tional data on acute cardiac effects of an intravenous
application.
Methods Echocardiography was performed in 18 healthy
volunteers after administration of a common high-dose
regimen of pantoprazole (80 mg i.v. bolus followed by
8 mg/h for 1 h) or placebo.
Design The design included a randomized, double-blind,
placebo-controlled cross-over trial.
Results Ejection fraction (%, mean ± SE) in the treat-
ment group (placebo group) was 60.7 ± 1.1 (61.2 ± 1.7)
at baseline, and 62.6 ± 1.1 (62.1 ± 1.9), 64.7 ± 1.6
(63.5 ± 1.3), 62.6 ± 1.6 (61.0 ± 1.6) and 63.0 ± 1.4
(61.8 ± 1.5) at 7.5, 15, 30 and 60 min after bolus appli-
cation, respectively (p = n.s.). Similarly, no signiﬁcant
changes were found for cardiac output, cardiac index,
blood pressure and heart rate. In contrast, gastric pH that
was used as a treatment control was signiﬁcantly increased
60 min after the application of pantoprazole as compared
to baseline and to placebo.
Conclusions Pantoprazole as injection is safe in healthy
subjects with respect to cardiac contractile function.
However, in view of recent reports of negative inotropy of
the drug, further studies in heart failure patients are
required.
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Introduction
Proton pump inhibitors (PPIs) are extensively used in the
treatment of acid-related gastrointestinal diseases [28]. In
Germany, anti-ulcer/gastrointestinal reﬂux products
accounted for €1.4 billion gross pharmacy sales in 2007,
and two different PPIs ranked among the 15 top-selling
drugs [9]. Three PPIs, namely pantoprazole, omeprazole
and esomeprazole, are currently available as intravenous
formulations in Europe. The rationale for use has come
primarily with the suggested efﬁcacy in reducing reblee-
ding after endoscopic treatment of bleeding peptic ulcers
(e.g., 19, 30). The target goal for gastric pH in these
patients has been suggested to be[6 in order to promote
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the target pH of[4 for preventing stress ulcer in patients,
or healing ulcers or reﬂux esophagitis. As such, the dosing
amounts of i.v. PPIs have been higher than that of oral PPIs
[19, 28, 30].
Yet, it has been known for several years that the effects
of PPIs are not strictly limited to gastric parietal cells.
Relaxation of smooth muscle cells has been implicated
from experiments with human and guinea pig airway
smooth muscle [23] and isolated arteries from rats [21],
guinea pigs and humans [23]. Moreover, we have recently
demonstrated negative inotropy of pantoprazole in isolated
myocardium of humans and rabbits [25]. This was dose-
dependent, induced nearly complete inhibition of twitch
force at high-doses and was partially reversible. Similar
results have been obtained with esomeprazole, which is
suggestive of a class effect of PPIs. The subcellular
mechanisms of cardiac effects of pantoprazole were dis-
tinct from the effects in gastric cells and involved changes
in intracellular Ca
2? transients and impaired Ca
2?
responsiveness of the myoﬁlaments. Also, we have
deduced from the in vitro ﬁndings that negative inotropy
may be of clinical relevance when using common thera-
peutic doses [25].
Recent reports on heart-related problems in two small,
long-term clinical studies of patients treated with oral
PPIs for severe gastroesophageal reﬂux disease have
caused extensive safety reviews by the US Food and Drug
Administration (FDA). On December 10, 2007, the FDA
concluded that long-term use of oral omeprazole or
esomeprazole is not likely to be associated with an
increased risk of heart problems [6]. However, none of
the evaluated studies was speciﬁcally conducted to assess
the risk of heart problems and patient follow-up was
incomplete. Moreover, studies investigating the acute
effects of intravenous high-dose PPIs on left ventricular
function are missing. The present study investigated the
effects of i.v. pantoprazole on left ventricular function in
healthy volunteers using a common high-dose regimen
[30]. Echocardiography was used because in clinical
practice, the vast majority of clinical decisions involving
left ventricular function are based on echocardiographic
ﬁndings.
Materials and methods
Participants
Enrollment of test persons was performed from 15 May
2005 until 27 January 2006 in the Department of Cardi-
ology and Pneumology, University Medical Center
Go ¨ttingen, Germany. For inclusion and exclusion criteria,
see Table 1. Volunteers were thoroughly examined and
routine laboratory parameters, ECG recordings and echo-
cardiography were analyzed. Volunteers were excluded if
any pathologic ﬁnding was present. Moreover, only sub-
jects with excellent sonographic conditions were included.
For baseline characteristics, see Table 2. The study com-
plies with the Declaration of Helsinki. The ethics
committee of the University of Go ¨ttingen approved the
research protocol and informed consent was obtained from
all subjects.
Study design, sample size and randomization
A double-blind, placebo-controlled cross-over design was
applied [27]. The sample size was calculated according to
the change in ejection fraction (EF) as an effect of pan-
toprazole that was meant to be detected. The expected
standard deviation was derived from historical data [10,
14]. Assuming a power of 0.90 and an alpha-level of 0.05,
we calculated that 14 subjects would be sufﬁcient for the
detection of an absolute difference in EF of 6%. To allow
for dropout, ten females and ten males were randomized.
Half of each gender group received pantoprazole on study
day 1 and placebo on study day 2 (protocol 1), and the
other half inversely (protocol 2). Stratiﬁed block ran-
domization was used to balance the number of men and
women (Fig. 1). During the preliminary examination, a
treatment time was assigned to each participant. From this
treatment time, a study number was derived, where each
study number was assigned to one of the two groups by
the statistician beforehand. Two subjects, one female and
one male, dropped out because of drug mixup on study
day 2.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age, 18–40 years History of cardiac disease
No clinically overt signs
of heart failure
History of other relevant
pre-existing illness
Echocardiographic ejection
fraction C55%
Pathologic ﬁndings in
clinical examinations
Excellent sonographic
conditions
Pathologic
echocardiographic
ﬁndings
Non-smoker Pathologic ECG ﬁndings
Pathologic laboratory
ﬁndings
Pregnancy and lactation
No or insufﬁcient
contraception
Intolerance of pantoprazole
Alcohol or drug abuse
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123Pharmaceuticals
Pantoprazole sodium powder for injection was purchased
from Altana Pharma AG, Konstanz, Germany. NaCl 0.9%
was purchased from DeltaSelect GmbH, Pfullingen,
Germany. Preparations of test substances were of identical
aspect and were done by the pharmacy of the University
Medical Center Go ¨ttingen, where also the randomization
list was kept.
Gastric pH
For gastric pH measurement, a Slimline
 single-use pH
catheter (Medtronic GmbH, Du ¨sseldorf, Germany) con-
nected to a Digitrapper
TM pH 400 recorder (Medtronic
GmbH, Du ¨sseldorf, Germany) was used. The display was
covered to exclude examiner bias during further measure-
ments. After the study procedure, data were read with
Polygram Net
TM 4.01 software (Medtronic GmbH, Du ¨s-
seldorf, Germany). Analyses were performed computerized
after completion of the trial.
Holter ECG
Holter ECG was recorded using a Lifecard CF digital
Holter recorder (Spacelabs Healthcare GmbH, Feucht,
Germany). Digital data were analyzed after completion of
the trial by Pathﬁnder Digital software (Spacelabs
Healthcare GmbH, Feucht, Germany). The mean heart
rates for 1-min-intervals were calculated.
Table 2 Baseline characteristics of healthy volunteers
All
n = 18
Female
n = 9
Male
n = 9
Protocol 1
n = 9
Protocol 2
n = 9
Age (years) 24.3 ± 0.4 24.0 ± 0.4 24.6 ± 0.8 24.1 ± 0.4 24.4 ± 0.8
Body mass index (kg/m
2) 22.7 ± 0.4 21.5 ± 0.5 23.8 ± 0.5 22.7 ± 0.6 22.6 ± 0.6
Body surface area (m
2) 1.87 ± 0.03 1.75 ± 0.01 1.99 ± 0.03 1.85 ± 0.05 1.89 ± 0.05
Resting blood pressure (mmHg)
Systolic 121.3 ± 1.6 118.3 ± 2.4 124.2 ± 2.0 121.7 ± 2.6 120.8 ± 2.0
Diastolic 69.2 ± 1.7 70.4 ± 2.2 67.9 ± 2.5 72.1 ± 2.5 66.3 ± 2.1
Resting heart rate (/min) 66.8 ± 1.5 66.6 ± 2.1 67.1 ± 2.1 65.9 ± 2.1 67.8 ± 2.0
Resting ejection fraction (%) 60.9 ± 1.0 61.4 ± 1.4 60.4 ± 1.5 60.5 ± 1.4 61.3 ± 1.5
Mean baseline characteristics (±SE) of 18 volunteers are shown. Protocol 1 means persons who were randomized to receive pantoprazole on day
1 and placebo on day 2, and protocol 2 inversely. There were no statistically signiﬁcant differences between groups
Fig. 1 Flowchart of
participation in the study
Clin Res Cardiol (2009) 98:391–399 393
123Blood pressure
Non-invasive blood pressure measurements were done
using an automatic inﬂation blood pressure monitor Omron
705IT (Omron Medizintechnik GmbH, Mannheim,
Germany).
Echocardiography
2D- and continuous wave (CW) Doppler echocardiography
with standard axis views were performed by one highly
experienced cardiologist using a Sonos 7500 (Philips
Medizin Systeme GmbH, Hamburg, Germany) ultrasound
machine according to the recommendations of the Ameri-
can Society of Echocardiography [10, 18, 22]. For volume
measurements, three loops in the apical 4-chamber view
were digitally saved at each sample interval during quiet
respiration. For measurement of velocity–time integral
(VTI), the transducer was angulated to position the path of
the CW Doppler in line with the left ventricular outﬂow
tract (LVOT). Three velocity signals at each sample
interval were saved. For measurement of LVOT diameter
(DLVOT), three beats in the parasternal long axis view
zoomed on the aortic valve were placed in a cine-loop.
DLVOT was measured at the base of the aortic cusps at peak
of systole (aortic valve maximally open), using inner edge
to inner edge. The largest of the three measurements was
taken and was further used in all serial measurements.
Analyses were performed blinded after completion of
the trial using Philips Xcelera 1.2 L4 software (Philips
Medizin Systeme GmbH, Hamburg, Germany). Left ven-
tricular volumes were calculated according to the single-
plane method of discs [10, 18]. End-diastole was deﬁned as
the frame in which the QRS complex appeared. End-
systole was deﬁned by the frame preceding initial early
diastolic mitral opening, which corresponded to the
smallest visible cavity area. EF was calculated as
EF (%Þ¼100  ð EDV   ESVÞ=EDV:
Cross-sectional area (CSA) of LVOT was calculated as
CSA(cm2Þ¼D2
LVOT   p=4:
Measurements of CW Doppler velocities were taken
from the outer border and the velocity–time integral (VTI)
was measured. CO was calculated as
CO (L=minÞ¼ð CSA   VTI   HRÞ=1000
at which heart rate (HR) was averaged over 1 min at each
sample interval [22]. Averaged heart rates were similar to
the respective instantaneous heart rates measured with the
echo machine or the blood pressure monitor. CI was
calculated as
CI [L=ðmin m2Þ  ¼ CO=BSA
and body surface area (BSA) was calculated from height
and weight according to the formula of DuBois and DuBois
[4].
Interventions and blinding
Pantoprazole 80 mg given intravenously over 2 min, fol-
lowed by 8 mg/h [30] was applied by a Perfusor fm (B.
Braun AG, Melsungen, Germany). Alternatively, NaCl
0.9% was applied in an identical manner. The test subject as
well as the examiner and all assistant personnel were blin-
ded toward the nature of the test substance. All parameters
were measured 5–10 min before bolus application (base-
line, BL) and 7.5, 15, 30 and 60 min (echocardiography,
blood pressure) or continuously thereafter (gastric pH,
Holter ECG). Adverse reactions were noted and the inten-
sity was quantiﬁed by a numeric analog scale ranging from
1 to 10. Examination with the comparator substance was
done after at least 5 and not later than after 14 days.
Statistical methods
Classical cross-over analyses, which account for treatment,
period and carry-over effects [27] were performed sepa-
rately for each point in time. Neither of these effects was
statistically signiﬁcant at an alpha-level of 0.05 (Table 3).
In particular, the estimated treatment effects on EF at
the single times reached from -1.2 to 0.7, which is below
the expected effect of 6%. For calculating the true power of
the cross-over analyses for the detection of EF-changes
under treatment, we determined the standard deviation of
the measured EFs and proceeded as in the sampling frame.
Thus, we received a power of 0.98 for the detection of
changes of 6% with the remaining 18 subjects.
As there was no signiﬁcant carry-over effect, we com-
bined the two periods and modeled both EF and CI, as a
mixture of treatment- and time-effect as well as a (treat-
ment 9 time)-interaction. Again, no signiﬁcant effect could
be detected at an alpha-level of 0.05 (Table 4). pH values
between treatment and control group (or between times)
were compared by an analysis of variance for longitudinal
data. All analyses were carried out using the statistic soft-
ware R and SAS. Data are presented as mean ± SE.
Results
Basic clinical parameters and adverse reactions
Systolic and diastolic blood pressure measured non-inva-
sively did not show any statistically signiﬁcant differences
394 Clin Res Cardiol (2009) 98:391–399
123over 60 min after application of pantoprazole as compared
to baseline or to placebo. Similarly, heart rate, which was
averaged over 1 min at each sample interval did not
demonstrate any statistically signiﬁcant change as a result
of treatment with pantoprazole or placebo (Fig. 2). Test
substances were well tolerated and test persons reported
few adverse reactions. Irritation of the throat by the pH
catheter was reported by seven persons with an intensity of
1–5, irritation of the injection site by three (intensity 2–3),
abdominal pain by two (2–3), sweetish taste by one (1), and
heartburn by one person (2) on a scale of 1–10 each. There
was no signiﬁcant increase of adverse reactions as a result
of treatment with pantoprazole compared to placebo.
Left ventricular ejection fraction, cardiac output
and cardiac index
Results of echocardiographic evaluation of left ventricular
function in the presence of pantoprazole or placebo are
summarizedinTable 3.Therewasnostatisticallysigniﬁcant
change in left ventricular EF over 60 min in subjects
receiving a common dosing regimen of pantoprazole when
compared to baseline measurements before bolus applica-
tion. Also, no signiﬁcant differences in EF were found when
compared to placebo infused to the same subjects in an
identical manner. In addition, there were no signiﬁcant
changesinCOandCIover60 minasaresultofpantoprazole
infusion compared to baseline or compared to placebo.
Gastric pH
Figure 3 demonstrates a typical gastric pH proﬁle under
treatment with pantoprazole or placebo in the same subject
and statistical data of all subjects. At 60 min after the bolus
application of pantoprazole, gastric pH was 3.9 ± 0.5. This
was signiﬁcantly different from baseline (1.6 ± 0.1, p\
0.001) and from placebo (1.7 ± 0.3, p\0.001). However,
it should be mentioned that the measurement of gastric pH
does not reﬂect actual acid secretion, but actual acid con-
tent, which depends on peristalsis and is not directly
inﬂuenced by pantoprazole. In a recent study, acid secre-
tion was fully inhibited within 1 h after administration of
80 mg of pantoprazole [7]. In the present study, an increase
in pH usually occurred 30–45 min after administration. In
some subjects, no increase in pH was seen in the obser-
vation period. This was ascribed to test conditions with
subjects having fasted for at least 4 h and lying quietly on
the left lateral decubitus during the observation period.
These hampered or slowed down the emptying of the
Table 3 Hemodynamics with pantoprazole
Mean (±SE) p values of evaluated effects
Time (min) Pantoprazole
n = 18
Placebo
n = 18
Carry-over Treatment Period
EF (%) BL 60.7 ± 1.1 61.2 ± 1.7 0.55 0.69 0.69
7.5 62.6 ± 1.0 62.1 ± 1.9 0.85 0.54 0.29
15 64.7 ± 1.6 63.5 ± 1.3 0.43 0.57 0.09
30 62.6 ± 1.6 61.0 ± 1.6 0.46 0.73 0.23
60 63.0 ± 1.4 61.8 ± 1.5 0.88 0.96 0.70
CO (L/min) BL 5.7 ± 0.3 5.3 ± 0.2 0.08 0.29 0.31
7.5 5.7 ± 0.2 5.5 ± 0.3 0.60 0.38 0.41
15 5.5 ± 0.3 5.3 ± 0.2 0.39 0.23 0.88
30 5.6 ± 0.3 5.5 ± 0.2 0.68 0.80 0.30
60 5.5 ± 0.3 5.6 ± 0.2 0.75 0.31 0.47
CI [L/(min m
2)] BL 3.0 ± 0.1 2.8 ± 0.1 0.05 0.38 0.22
7.5 3.0 ± 0.1 3.0 ± 0.1 0.61 0.54 0.40
15 2.9 ± 0.1 2.8 ± 0.1 0.35 0.25 0.81
30 3.0 ± 0.1 2.9 ± 0.1 0.61 0.87 0.16
60 2.9 ± 0.1 3.0 ± 0.1 0.79 0.42 0.38
Mean (±SE) are shown. No statistically signiﬁcant differences were found
BL baseline, EF ejection fraction, CO cardiac output, CI cardiac index
Table 4 p values in the mixture model analysis
Treatment Point in time Interaction
(treatment 9 point in time)
EF 0.46 0.07 1.0
CI 0.30 0.42 0.49
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123gastric acid to the duodenum. In other subjects receiving
placebo, pH alternated between acidic and neutral values,
reﬂecting temporal loss of contact of the pH catheter with
gastric acid because of gastric peristalsis.
Discussion
The present study shows that a common high-dose regimen
of pantoprazole (80 mg over 2 min followed by 8 mg/h
i.v.), usually applied for reducing rebleeding after endo-
scopic treatment of bleeding peptic ulcers [30], did not
result in clinically relevant impairment of left ventricular
function and hemodynamics in healthy volunteers. We
demonstrated that left ventricular EF did not signiﬁcantly
change over 60 min after application of pantoprazole as
compared to baseline or to placebo. Also, no signiﬁcant
changes in cardiac output, cardiac index or any basic
hemodynamic parameter were found. In contrast, gastric
pH that was used as a treatment control was signiﬁcantly
increased 60 min after the application of pantoprazole as
compared to baseline and to placebo.
Pharmacology of PPIs
With respect to gastric proton pump inhibition, all PPIs are
prodrugs and require activation by protonation at low pH.
Following activation, PPIs undergo a series of chemical
reactions that culminate in covalent binding to the gastric
proton pump. Moreover, protonation converts the drug
from a lipophilic to a hydrophilic form that can no longer
permeate cell membranes. For these reasons, in parietal
cells, PPIs become trapped after protonation and exhibit a
substantial accumulation versus plasma at low pH, making
Fig. 2 Mean ± SE of systolic and diastolic blood pressure (a) and of
heart rate (b) at baseline (BL) and during application of a
pantoprazole high-dose regimen (cf. ‘‘Materials and methods’’) as
compared to placebo (n = 18 each)
Fig. 3 Original recordings of typical gastric pH proﬁles of a healthy
subject under treatment with pantoprazole (a) or placebo (b). c Box
and whiskers plots showing median pH and 25–75% quartiles of
gastric pH in healthy volunteers under treatment with pantoprazole or
placebo at baseline (BL) and after 60 min. Outliers are marked with
circles (n = 18 each)
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123the inhibitory effect of PPIs on proton pumps independent
of plasma concentrations [28]. Recently, our group has
reported on negative inotropy of pantoprazole in isolated
myocardium of humans and rabbits [25]. In contrast to the
subcellular mechanisms of PPIs in gastric cells, the effects
in myocardium were suggested to be independent of acti-
vation at low pH, because negative inotropy occurred at pH
7.3–7.4. Moreover, in contrast to proton pump inhibition,
the effects in the myocardium were at least partially
reversible within few minutes after washout of the drug.
Hence, we concluded that the potential effects of PPIs on
contractile function in vivo may depend on plasma con-
centrations of the unprotonated native drug. However, in
vivo PPIs are quickly eliminated from blood with plasma
elimination half-lives of about 1–2 h [17, 26]. We therefore
anticipated that in the present study, the potential impair-
ment of left ventricular function during an identical
infusion regimen of pantoprazole should be maximum at
the time of maximum plasma concentrations, i.e., shortly
after bolus application. For the same reason, no extended
observations over several hours or days were performed in
the present study.
Reasons for the absence of clinically relevant cardiac
effects
What might be the potential reasons for the absence of a
clinically relevant effect of pantoprazole on cardiac per-
formance and hemodynamics in the present study in view
of our recent ﬁndings in isolated myocardium? It is
obvious that one has to be cautious in extrapolating in
vitro ﬁndings to the clinical situation, because ﬁndings
seen directly on the myocardial level may be masked in
vivo by physiological effects such as preload, afterload,
neurohumoral activation and heart rate. In this regard, it is
noteworthy that heart rate was unchanged, which might
have been indicative of an increased sympathetic tone as
a compensatory mechanism. Moreover, cardiac side
effects may be attenuated in vivo, because the activity of
the free compound may be substantially lower because of
high plasma protein binding. Recently, although 40 mg
pantoprazole gave a serum concentration–time curve
(AUC) of the total parent compound of 10.5 lmol h/L,
the high plasma protein binding of pantoprazole of 98%
reversed the AUC value for the free drug to 0.19 lmol h/L
[17]. Yet, PPIs show characteristic pharmacokinetic prop-
erties that may speciﬁcally inﬂuence the potency of cardiac
effects. Forexample,the fraction ofdrugunboundtoplasma
was reported as: omeprazole 0.05, esomeprazole 0.05,
rabeprazole 0.04, lansoprazole 0.03 and pantoprazole 0.02
[28]. Greater fraction of active free compound might
therefore indicate superior potency with regard to cardiac
effects.
Accuracy of methods
One might argue that the accuracy of echocardiography
was not sufﬁcient for the detection of small changes in left
ventricular EF. However, during the last decades, echo-
cardiographic methods and techniques have improved and
expanded dramatically. It was shown that echocardiogra-
phy can be performed with a high degree of reproducibility
and that it was a reliable tool for the quantiﬁcation of left
ventricular function in numerous clinical trials [10, 18, 22].
Poor endocardial deﬁnition, the most frequent pitfall in 2D
echocardiographic evaluation of left ventricular function
[10, 18, 22], was circumvented in the present study by only
including subjects with excellent imaging conditions.
Recently, in clinical trials, changes in left ventricular EF of
6–9% were detected by echocardiography in patients with
congestive heart failure under treatment with b-blockers,
which have been considered as clinically relevant [3, 10,
12]. The present study was powered to detect changes in
left ventricular EF of at least 6% when calculation was
done using published data. The true power of the present
study using the standard deviations of the measured EFs
was 0.98. Thus, our study was sufﬁciently accurate to
detect clinically relevant effects of a high-dose regimen of
pantoprazole on left ventricular function.
Implications for particular patients
Although healthy subjects may well tolerate high doses of
pantoprazole, particular patients may be prone to cardiac
side effects of PPIs. In isolated human and rabbit myo-
cardium, pantoprazole has been shown to affect the
contractile force by two mechanisms: (1) reduction in the
amplitude of Ca
2? transients as a consequence of impaired
SR Ca
2? uptake and reduced Ca
2? inﬂux via ICa,L
(2) reduced Ca
2? responsiveness of the myoﬁlaments as a
result of a reduced maximal active tension and a slightly
lower Ca
2? sensitivity [25]. In the end-stage failing human
heart, development of contractile dysfunction is crucially
caused by abnormalities of intracellular Ca
2? cycling and
sarcomeric proteins. Decreased expression and function of
SR Ca
2?–ATPase, increased forward mode Na
?–Ca
2?
exchange activity as well, as dysfunction of the ryanodine
receptor promoting impairment of systolic and diastolic
Ca
2? transients have been described [13]. Moreover, dys-
functions of myoﬁlaments that are probably caused by
altered post-translational modiﬁcation, in particular the
phosphorylation state of troponins I and T and possibly
myosin light chain, have been found [20]. Hence, subcel-
lular mechanisms underlying heart failure may be
potentiated by treatment with high doses of pantoprazole.
Further mechanisms of heart failure have been described
[2, 5, 15, 24, 29]. Moreover, patients with heart failure are
Clin Res Cardiol (2009) 98:391–399 397
123much more susceptible to negative inotropic drugs because
of blunted contractile reserve subsequent to decreased
sympathetic sensitivity [1] or negative force–frequency
relationship [13]. Furthermore, certain patients may have
considerably higher plasma concentrations of PPIs. All
PPIs undergo extensive hepatic biotransformation before
elimination. In CYP2C19-poor metabolizers that represent
approximately 3–5% of Caucasians, a similar percentage of
African–Americans and 12–25% of different Asian popu-
lations, much higher plasma concentrations and longer
elimination half-lives have been found [28]. The same
holds true for patients with severe liver impairment [8].
Conclusions
In conclusion, this study indicates that pantoprazole for
injection is safe in healthy subjects with regard to cardiac
contractile function when using a common high-dose reg-
imen. Yet, it cannot be ruled out that ultra-high doses might
impair function of normally beating hearts in vivo. Also,
the effects of repetitive or continuous applications of high
doses or application over prolonged periods have not been
investigated for cardiac side effects in a prospective study.
As long as there is no safety data, impairment of cardiac
function should be taken into account in patients with heart
failure or patients with combined heart and liver disease, as
well as in particular situations like acute intoxication with
ultra-high doses of pantoprazole. Moreover, in view of
recent studies showing that appropriate use of intravenous
PPIs was only seen in less than half of the patients [11, 16],
treatment with intravenous PPIs should be discontinued as
soon as the patient is able to be treated with oral
formulations.
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